1. Home
  2. FKWL vs NXTC Comparison

FKWL vs NXTC Comparison

Compare FKWL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Wireless Corp.

FKWL

Franklin Wireless Corp.

HOLD

Current Price

$3.74

Market Cap

44.7M

Sector

Utilities

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$8.97

Market Cap

39.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FKWL
NXTC
Founded
1981
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.7M
39.1M
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
FKWL
NXTC
Price
$3.74
$8.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$23.00
AVG Volume (30 Days)
6.0K
63.2K
Earning Date
05-15-2026
05-04-2026
Dividend Yield
1.10%
N/A
EPS Growth
94.12
N/A
EPS
0.10
N/A
Revenue
$46,086,901.00
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.14
N/A
P/E Ratio
$37.30
N/A
Revenue Growth
49.65
N/A
52 Week Low
$3.52
$0.34
52 Week High
$5.48
$15.74

Technical Indicators

Market Signals
Indicator
FKWL
NXTC
Relative Strength Index (RSI) 52.39 44.55
Support Level $3.73 $8.42
Resistance Level $3.94 $13.94
Average True Range (ATR) 0.07 1.36
MACD 0.01 -0.18
Stochastic Oscillator 77.27 25.76

Price Performance

Historical Comparison
FKWL
NXTC

About FKWL Franklin Wireless Corp.

Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: